Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Must have received: systemic therapy — relapsed/refractory CLL/SLL or MCL

disease that relapsed after, or was refractory to, at least 1 prior therapy

Cannot have received: BCL2 inhibitor

Exposure to a Bcl-2 inhibitor within the last 12 months or a history of disease progression while taking a Bcl-2 inhibitor

Cannot have received: autologous stem cell transplant

Exception: unless >= 3 months after transplant

Prior autologous stem cell transplant unless >= 3 months after transplant

Cannot have received: CAR-T cell therapy

Exception: unless >= 3 months after cell infusion

prior chimeric antigen receptor T-cell (CAR-T) therapy unless >= 3 months after cell infusion

Cannot have received: allogeneic stem cell transplant

Exception: with active graft-versus-host disease (GVHD), or requiring immunosuppressive drugs for the treatment of GVHD, or have taken calcineurin inhibitors within 4 weeks prior to consent

Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD), or requiring immunosuppressive drugs for the treatment of GVHD, or have taken calcineurin inhibitors within 4 weeks prior to consent

Cannot have received: biologic and/or immunologic-based therapy (rituximab)

Any biologic and/or immunologic-based therapy(ies) including experimental therapy(ies) for leukemia, lymphoma, or myeloma (including, but not limited to, monoclonal antibody therapy, e.g., rituximab, and/or cancer vaccine therapy) <= 28 days before the first dose

Cannot have received: systemic chemotherapy

Systemic chemotherapy or radiation therapy <= 14 days before the first dose

Cannot have received: radiation therapy

Systemic chemotherapy or radiation therapy <= 14 days before the first dose

Cannot have received: corticosteroid

Corticosteroid given with antineoplastic intent <= 7 days before the first dose

Cannot have received: Bruton's tyrosine kinase inhibitor

Bruton's tyrosine kinase inhibitor (BTKi) or other small molecule inhibitor is given with antineoplastic intent <= 3 days (or 5 half-lives; whichever is shorter) before the first dose